Related Experiment Video

Updated: Jul 16, 2026

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

[After the LDL receptor and apolipoprotein B, autosomal dominant hypercholesterolemia reveals its third protagonist:

M Abifadel1, J-P Rabès, C Boileau

  • 1Inserm, U781, Paris, France. abifadel@necker.fr

Annales D'Endocrinologie
|March 30, 2007
PubMed

Insights

Proprotein Convertase Subtilin Kexin 9 (PCSK9) is the third gene linked to autosomal dominant hypercholesterolemia. PCSK9 mutations impact cholesterol levels, offering new therapeutic targets.

Area of Science:

  • Genetics and Molecular Biology
  • Cardiovascular Disease Research

Context:

  • Autosomal dominant hypercholesterolemia was historically linked to two genes: the low-density lipoprotein receptor and apolipoprotein B.
  • The discovery of PCSK9 (Proprotein Convertase Subtilin Kexin 9) in 2003 identified a third key gene involved in this condition.

Purpose:

  • To highlight the identification and role of PCSK9 in hypercholesterolemia.
  • To explore the impact of various PCSK9 mutations on cholesterol metabolism and cardiovascular health.

Summary:

  • Gain-of-function mutations in PCSK9 lead to hypercholesterolemia by reducing LDL receptor levels.
  • Loss-of-function mutations, such as p.Y142X and p.C679X, are associated with hypocholesterolemia and reduced cardiovascular risk, particularly in Black Americans.
  • PCSK9 plays a significant role in cholesterol homeostasis, although its precise substrates and functions are still under investigation.

Impact:

  • PCSK9 is a crucial factor in cholesterol homeostasis.
  • PCSK9 inhibitors represent promising therapeutic targets for lowering LDL cholesterol and may work synergistically with statins.

More Related Videos

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK908:14

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9

Published on: August 28, 2018

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Receptor-mediated Endocytosis01:38

Receptor-mediated Endocytosis

Overview
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...